Navigation Links
Spherix Reports 2007 Financial Results

BETHESDA, Md., April 3, 2008 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) reported a net loss of $938,000 for the year ended December 31, 2007. The Company's research and development costs jumped to $5.9 million in 2007, from $884,000 in 2006, with the launch of the Company's Phase 3 clinical trial for Naturlose as a treatment for Type 2 diabetes in April 2007. The trial is expected to last at least two years, and will be financed through the proceeds received from the sale of the Company's InfoSpherix subsidiary. The Company's losses from continuing operations were $5.9 million and $700,000 for the years ended 2007 and 2006, which includes income tax benefit allocations of $3.4 million and $2.4 million each. Income from discontinued operations was $4.9 million and $4.2 million for each of the years ended 2007 and 2006, net of income tax expense allocations of $4.2 million and $2.5 million. Income from discontinued operations in 2007 included an $8.6 million pre-tax gain on the sale of our InfoSpherix subsidiary.

(Numbers in 000's)

2007 2006

Revenue $155 $7

Loss from continuing operations (5,851) (700)

Income from discontinued operations 4,913 4,213

Net (loss) income (938) 3,513

Net (loss) income per share

Continuing operations $ (0.41) $ (0.05)

Discontinued operations $ 0.35 $ 0.31

Net (loss) income per share $ (0.07) $ 0.26

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is

SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Reports 3rd Quarter Earnings
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. Genetic Engineering & Biotechnology News reports on cancer biomarkers
4. Derma Sciences Reports Fourth Quarter Year-End Results for 2007
5. China Bio Energy Reports Fiscal 2007 Financial Results
6. Laureate Pharma Reports Record Growth for 2007
7. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
8. PharmAthene Reports Year-End 2007 Financial Results
9. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
10. Photonic Products Group, Inc. Reports Record Financial Results for FY 2007
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is ... 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... wide range of applications such as, but not limited to, biotechnology, biomedical, drug ...
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
Breaking Biology News(10 mins):